title: [Economic impact of hemophilia type A and B in Mexico].
abstract: BACKGROUND
  The treatment of hemophilia generates a disproportionally large economic impact relative to its prevalence.
  
  
  OBJECTIVE
  To determine the economic impact of hemophilia A and B in Mexico in 2011 from the perspective of public health institutions.
  
  
  METHODS
  Hemophilia was epidemiologically characterized in Mexico during the year of interest, direct costs (diagnosis, monitoring or follow-up, care of bleeding events, and consumption of hemostatic factors), as well as absenteeism associated with illness (indirect costs) were estimated. Records, surveys and official data were supplemented by expert opinion to assess costs.
  
  
  RESULTS
  The investment in hemostatic factors is the primary source of cost: 68.6 and 74.3% of total investment in hemophilia A and B, respectively. Sensitivity analysis showed that the most decisive variable is the cost of acquisition of hemostatic factors, including bypass agents. The second most important source of cost is the attention to bleeding events, being significantly higher in patients receiving on-demand treatment compared with those receiving prophylaxis.
  
  
  CONCLUSIONS
  In Mexico, hemophilia is a condition whose treatment requires a large amount of financial resources associated with the cost of hemostatic factors and care of hemorrhage, the latter being lower in patients on prophylaxis relative to on-demand.
authors.affiliation: R A C Salud Consultores S.A. de C.V.
authors.forename: Fernando
authors.initials: F
authors.lastname: Carlos-Rivera
authors.affiliation: R A C Salud Consultores S.A. de C.V.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Gasca-Pineda
authors.affiliation: Instituto Mexicano del Seguro Social. México, D.F., México.
authors.forename: Abraham
authors.initials: A
authors.lastname: Majluf-Cruz
authors.affiliation: Instituto Mexicano del Seguro Social. México, D.F., México.
authors.forename: Jaime
authors.initials: J
authors.lastname: García-Chávez
mesh_terms: D000328:Adult; D002648:Child; D003365:Costs and Cost Analysis; D006467:Hemophilia A / Q000191:economics* / Q000628:therapy; D002836:Hemophilia B / Q000191:economics* / Q000628:therapy; D006801:Humans; D008800:Mexico